Nally Michael 4

What Happened
Michael Nally, CEO of Generate Biomedicines (GENB), reported a purchase of 20,000 shares on 2026-03-04 at $12.00 per share, for a total cost of $240,000. The Form 4 lists the transaction as a purchase (code P), described as an open market or private purchase.

Key Details

• Transaction date: 2026-03-04
• Transaction type/code: Purchase (P) — open market or private purchase (Form 4 does not specify which)
• Price and size: 20,000 shares at $12.00 each; total $240,000
• Shares owned after transaction: Not disclosed on the reported Form 4
• Footnote: F1 — the reporting person disclaims beneficial ownership for Section 16 purposes except to the extent of any pecuniary interest. In short, Mr. Nally disclaims beneficial ownership other than any financial interest.
• Filing date/timeliness: Form filed 2026-03-06 (two days after the transaction), which appears to be within the typical two-business-day Form 4 reporting window.

Context
This is a straightforward insider purchase (not an option exercise, grant, gift, or tax withholding). Insider purchases can be of interest to retail investors as one data point, but they do not, by themselves, prove future company performance. No 10b5‑1 plan, derivative transactions, or other special conditions were reported in this filing.